The Manufacturers Life Insurance Company decreased its position in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 0.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 12,428 shares of the biotechnology company’s stock after selling 81 shares during the period. The Manufacturers Life Insurance Company owned 0.07% of Enanta Pharmaceuticals worth $447,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Parametric Portfolio Associates LLC increased its position in Enanta Pharmaceuticals by 20.2% during the first quarter. Parametric Portfolio Associates LLC now owns 11,854 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 1,989 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Enanta Pharmaceuticals by 2.9% in the first quarter. Teachers Advisors LLC now owns 25,182 shares of the biotechnology company’s stock worth $776,000 after acquiring an additional 700 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Enanta Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock worth $24,399,000 after acquiring an additional 53,007 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after acquiring an additional 233,265 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Enanta Pharmaceuticals by 5.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 53,312 shares of the biotechnology company’s stock worth $1,643,000 after acquiring an additional 2,736 shares in the last quarter. 66.45% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) opened at $47.86 on Monday. Enanta Pharmaceuticals Inc has a 52 week low of $25.92 and a 52 week high of $50.92. The company has a market cap of $913.65, a price-to-earnings ratio of 54.39 and a beta of 0.66.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The company had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. During the same quarter last year, the company earned ($0.09) earnings per share. The company’s revenue was up 491.3% compared to the same quarter last year. sell-side analysts expect that Enanta Pharmaceuticals Inc will post -1.57 EPS for the current year.

ENTA has been the subject of several recent research reports. Robert W. Baird increased their price objective on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 8th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $38.00 price objective (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research report on Wednesday, August 9th. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 11th. Royal Bank Of Canada initiated coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating for the company. Finally, JMP Securities increased their price objective on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Enanta Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $46.25.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/27/enanta-pharmaceuticals-inc-enta-position-lessened-by-the-manufacturers-life-insurance-company.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.